Javier Sanz

Javier Sanz

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in European Heart Journal
Verified
Journal Article
Open access
CAChristiane E Angermann
Christiane E Angermann
SSSusanne Sehner
Susanne Sehner
LGLouisa M S Gerhardt
Louisa M S Gerhardt
Carlos Garcia Santos-GallegoCarlos Garcia Santos-Gallego
Carlos Garcia Santos-Gallego
JRJuan Antonio Requena-Ibanez
Juan Antonio Requena-Ibanez
Juan J. BadimonJuan J. Badimon
Juan J. Badimon
Background and Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact iron metabolism in patients with heart failure but mechanisms are incompletely understood. This post hoc analysis explored interrelations between iron homeostasis, cardiac structure/function, exercise capacity, haematopoiesis, and sympathetic activity at baseline, and the effects of 6-month treatment with empagliflozin vs. placebo by anaemia status in EMPATROPISM-FE study participants. Methods: Myocardial iron content (MIC, estimated by cardiac magnetic resonance T2* imaging), left ventricular (LV) volumes and LV ejection fraction (LVEF), exercise capacity, laboratory iron markers (LIM), haemoglobin/haematocrit, erythropoietin, and plasma norepinephrine were determined at baseline and 6 months. Results: At baseline, 24/80 participants (30%) had anaemia (haemoglobin < 13/<12 mg/dL in men/women). Patients with vs. without anaemia had higher T2* (indicating lower MIC, P < .001), lower peak oxygen consumption (VO2max, P = .024) and hepcidin (P = .017), and higher erythropoietin (P = .040) and norepinephrine (P = .016). Across subgroups, lower MIC correlated with higher LV volumes (P < .01) and norepinephrine (P < .001), and lower LVEF (P < .01), VO2max (P < .001) and haemoglobin/haematocrit (P < .001). Associations with LIM were poor (all P > .10). Empagliflozin increased MIC (P < .012), improved exercise capacity, and activated haematopoiesis. Changes in LIM and norepinephrine suggested progressive systemic iron depletion and sympatholysis. LV reverse remodelling was greater in individuals with anaemia. Conclusions: Dysregulated cellular iron uptake/availability may be a shared mechanism in myocardial structural/functional impairment, reduced exercise capacity, and restricted haematopoiesis in heart failure, which are worse in patients with anaemia, and improve with empagliflozin. Empagliflozin increases MIC and decreases norepinephrine. Given this inverse association, sympatholysis may help explain the diverse cardiac and systemic benefits from SGLT2i therapy. Clinical Trial Registration: NCT03485222 (www.clinicaltrials.gov).

23 April 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
EPEva Sophie Lunde Pedersen
Eva Sophie Lunde Pedersen
Carmen De JongCarmen De Jong
Carmen De Jong
MJM Jurca
M Jurca
DBDo Berger
Do Berger
JSJavier Sanz
Javier Sanz
CRCs Rueegg
Cs Rueegg

Verified
Journal Article
Open access
PDF file
DKDennis Kraemer
Dennis Kraemer
DTDillenn Terumalai
Dillenn Terumalai
MFMaria Livia Famiglietti
Maria Livia Famiglietti
IFIsabel Filges
Isabel Filges
PJPascal Joset
Pascal Joset
ARAnita Rauch
Anita Rauch
Large-scale next-generation sequencing (NGS) germline testing is technically feasible today, but variant interpretation represents a major bottleneck in analysis workflows. This includes extensive variant prioritization, annotation, and time-consuming evidence curation. The scale of the interpretation problem is massive, and variants of uncertain significance (VUSs) are a challenge to personalized medicine. This challenge is further compounded by the complexity and heterogeneity of the standards used to describe genetic variants and the associated phenotypes when searching for relevant information to support clinical decision making. To address this, all five Swiss academic institutions for Medical Genetics joined forces with the Swiss Institute of Bioinformatics (SIB) to create SwissGenVar as a user-friendly nationwide repository and sharing platform for genetic variant data generated during routine diagnostic procedures and research sequencing projects. Its aim is to provide a protected environment for expert evidence sharing about individual variants to harmonize and upscale their significance interpretation at the clinical grade according to international standards. To corroborate the clinical assessment, the variant-related data will be combined with consented high-quality clinical information. Broader visibility will be achieved by interfacing with international databases, thus supporting global initiatives in personalized healthcare.